Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 494

1.

Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.

Reich K, Sinclair R, Roberts G, Griffiths CE, Tabberer M, Barker J.

Curr Med Res Opin. 2008 May;24(5):1237-54. doi: 10.1185/030079908X291985 . Epub 2008 Mar 19. Review.

PMID:
18355421
[PubMed - indexed for MEDLINE]
2.

Etanercept and efalizumab for the treatment of psoriasis: a systematic review.

Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. Review.

PMID:
17083854
[PubMed - indexed for MEDLINE]
Free Article
3.

An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.

Weinberg JM.

Clin Ther. 2003 Oct;25(10):2487-505. Review.

PMID:
14667953
[PubMed - indexed for MEDLINE]
4.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

PMID:
16948890
[PubMed - indexed for MEDLINE]
Free Article
5.

Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.

Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A.

Br J Dermatol. 2008 Aug;159(2):274-85. doi: 10.1111/j.1365-2133.2008.08673.x. Epub 2008 Jun 10. Review.

PMID:
18547300
[PubMed - indexed for MEDLINE]
6.

Cost effectiveness of biologic therapies for plaque psoriasis.

Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR.

Am J Clin Dermatol. 2013 Aug;14(4):315-26. doi: 10.1007/s40257-013-0030-z. Review.

PMID:
23696234
[PubMed - indexed for MEDLINE]
7.

[Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials].

Zhang Z, Schmitt J, Wozel G, Kirch W.

Med Klin (Munich). 2009 Feb 15;104(2):125-36. doi: 10.1007/s00063-009-1024-8. Epub 2009 Feb 26. German.

PMID:
19242664
[PubMed - indexed for MEDLINE]
8.

Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.

Mazzotta A, Esposito M, Costanzo A, Chimenti S.

Am J Clin Dermatol. 2009;10(5):319-24. doi: 10.2165/11310770-000000000-00000.

PMID:
19658444
[PubMed - indexed for MEDLINE]
9.

Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.

Reich K, Burden AD, Eaton JN, Hawkins NS.

Br J Dermatol. 2012 Jan;166(1):179-88. doi: 10.1111/j.1365-2133.2011.10583.x. Epub 2011 Nov 11. Review.

PMID:
21910698
[PubMed - indexed for MEDLINE]
10.

The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis.

Katugampola RP, Lewis VJ, Finlay AY.

Br J Dermatol. 2007 May;156(5):945-50. Epub 2007 Mar 28. Review.

PMID:
17388922
[PubMed - indexed for MEDLINE]
11.

Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.

Gordon K, Korman N, Frankel E, Wang H, Jahreis A, Zitnik R, Chang T.

J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S101-11.

PMID:
16488320
[PubMed - indexed for MEDLINE]
12.

A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.

Lebwohl MG, Kircik L, Callis Duffin K, Pariser D, Hooper M, Wenkert D, Thompson EH, Yang J, Kricorian G, Koo J.

J Am Acad Dermatol. 2013 Sep;69(3):385-92. doi: 10.1016/j.jaad.2013.03.031. Epub 2013 May 1.

PMID:
23643256
[PubMed - indexed for MEDLINE]
13.

Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.

Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W.

Arch Dermatol. 2005 Jan;141(1):31-8.

PMID:
15655139
[PubMed - indexed for MEDLINE]
14.

Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.

Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W.

Br J Dermatol. 2008 Sep;159(3):513-26. doi: 10.1111/j.1365-2133.2008.08732.x. Epub 2008 Jul 9. Review.

PMID:
18627372
[PubMed - indexed for MEDLINE]
15.

Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials.

Papp KA, Signorovitch J, Ramakrishnan K, Yu AP, Gupta SR, Bao Y, Mulani PM.

Clin Drug Investig. 2011;31(1):51-60. doi: 10.2165/11539360-000000000-00000.

PMID:
20932070
[PubMed - indexed for MEDLINE]
16.

Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.

Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB.

Br J Dermatol. 2005 May;152(5):954-60.

PMID:
15888152
[PubMed - indexed for MEDLINE]
17.

Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period.

Nelson AA, Pearce DJ, Fleischer AB Jr, Balkrishnan R, Feldman SR.

J Am Acad Dermatol. 2008 Jan;58(1):125-35. Epub 2007 Nov 8. Review.

PMID:
17996329
[PubMed - indexed for MEDLINE]
18.

Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.

Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M.

Dermatology. 2008;216(3):260-70. doi: 10.1159/000113150. Epub 2008 Jan 11.

PMID:
18187944
[PubMed - indexed for MEDLINE]
19.

Infliximab for the treatment of adults with psoriasis.

Loveman E, Turner D, Hartwell D, Cooper K, Clegg A.

Health Technol Assess. 2009 Jun;13 Suppl 1:55-60. doi: 10.3310/hta13suppl1/09.

PMID:
19567215
[PubMed - indexed for MEDLINE]
Free Article
20.

Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.

Kalb RE, Blauvelt A, Sofen HL, Chevrier M, Amato D, Calabro S, Wang J, Schenkel B, Gottlieb AB.

J Drugs Dermatol. 2013 Aug;12(8):874-80.

PMID:
23986160
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk